Skip to main content

Table 2 Prevalence of metabolic syndrome components in the four groups at baseline and at follow-up

From: Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study

Metabolic syndrome components Fatty liver status (n = 1344) Fatty liver status (n = 112) Fatty liver status (n = 251) Fatty liver status (n = 382)
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
No fatty liver No fatty liver Fatty liver No fatty liver No fatty liver Fatty liver Fatty liver Fatty liver
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Waist circumference, (men ≥90 cm/women ≥80 cm) 72 (5.4) 110 (8.2) 27 (24.1) 16 (14.3) 28 (11.2) 46 (18.3) 110 (28.8) 108 (28.3)
Triglyceride (TG ≥1.7 mmol/L or drug treatment) 215 (16.0) 213 (15.8) 50 (44.6) 40 (35.7) 112 (44.6) 123 (49.0) 205 (53.7) 202 (52.9)
HDL-C (HDL-C <1 mmol/L (men)/<1.3 mmol/L (women) or drug treatment) 90 (6.7) 100 (7.4) 6 (5.4) 12 (10.7) 19 (7.6) 45 (17.9) 20 (5.2) 52 (13.6)
Blood pressure (BP >130/85 mmHg or drug treatment) 69 (5.1) 172 (12.8) 8 (7.1) 28 (25.0) 16 (6.4) 53 (21.1) 24 (6.3) 99 (25.9)
Glucose (glucose ≥5.6 mmol/L or drug treatment) 106 (7.9) 232 (17.3) 16 (14.3) 37 (33.0) 20 (8.0) 73 (29.1) 59 (15.4) 131 (34.3)
Metabolic syndrome (presence of any three of the following five traits) 0 (0 %) 41 (3.1 %) 0 (0 %) 10 (8.9 %) 0 (0 %) 36 (14.3 %) 0 (0 %) 72 (18.8 %)
  1. Data are (n, %)